



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Anagliptin

March 20, 2018

### **Non-proprietary name**

Anagliptin

### **Safety measure**

Precautions should be revised in the package insert.

In the Important Precautions section, the following language should be added (revised language is underlined):

Acute pancreatitis may occur. Patients should be instructed to consult with a physician immediately if initial symptoms including persistent and intense abdominal pain and/or vomiting occur.

The following language should be added to the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

Acute pancreatitis:

Acute pancreatitis may occur. Patients should be carefully monitored. If any abnormalities, including persistent and intense abdominal pain and/or vomiting are observed, administration of this drug should be discontinued and appropriate measures should be taken.

Pemphigoid:

Pemphigoid may occur. If blister, erosion or other signs and symptoms are observed, patients should be referred to a dermatologist, and appropriate measures, such as

Pharmaceuticals and Medical Devices Agency

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

discontinuation of administration, should be taken.

**Pharmaceuticals and Medical Devices Agency**

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)